Literature DB >> 21885347

Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.

Owen A Ross1, Alexandra I Soto-Ortolaza, Michael G Heckman, Jan O Aasly, Nadine Abahuni, Grazia Annesi, Justin A Bacon, Soraya Bardien, Maria Bozi, Alexis Brice, Laura Brighina, Christine Van Broeckhoven, Jonathan Carr, Marie-Christine Chartier-Harlin, Efthimios Dardiotis, Dennis W Dickson, Nancy N Diehl, Alexis Elbaz, Carlo Ferrarese, Alessandro Ferraris, Brian Fiske, J Mark Gibson, Rachel Gibson, Georgios M Hadjigeorgiou, Nobutaka Hattori, John P A Ioannidis, Barbara Jasinska-Myga, Beom S Jeon, Yun Joong Kim, Christine Klein, Rejko Kruger, Elli Kyratzi, Suzanne Lesage, Chin-Hsien Lin, Timothy Lynch, Demetrius M Maraganore, George D Mellick, Eugénie Mutez, Christer Nilsson, Grzegorz Opala, Sung Sup Park, Andreas Puschmann, Aldo Quattrone, Manu Sharma, Peter A Silburn, Young Ho Sohn, Leonidas Stefanis, Vera Tadic, Jessie Theuns, Hiroyuki Tomiyama, Ryan J Uitti, Enza Maria Valente, Simone van de Loo, Demetrios K Vassilatis, Carles Vilariño-Güell, Linda R White, Karin Wirdefeldt, Zbigniew K Wszolek, Ruey-Meei Wu, Matthew J Farrer.   

Abstract

BACKGROUND: Background The leucine-rich repeat kinase 2 gene (LRRK2) harbours highly penetrant mutations that are linked to familial parkinsonism. However, the extent of its polymorphic variability in relation to risk of Parkinson's disease (PD) has not been assessed systematically. We therefore assessed the frequency of LRRK2 exonic variants in individuals with and without PD, to investigate the role of the variants in PD susceptibility.
METHODS: LRRK2 was genotyped in patients with PD and controls from three series (white, Asian, and Arab-Berber) from sites participating in the Genetic Epidemiology of Parkinson's Disease Consortium. Genotyping was done for exonic variants of LRRK2 that were identified through searches of literature and the personal communications of consortium members. Associations with PD were assessed by use of logistic regression models. For variants that had a minor allele frequency of 0·5% or greater, single variant associations were assessed, whereas for rarer variants information was collapsed across variants.
FINDINGS: 121 exonic LRRK2 variants were assessed in 15 540 individuals: 6995 white patients with PD and 5595 controls, 1376 Asian patients and 962 controls, and 240 Arab-Berber patients and 372 controls. After exclusion of carriers of known pathogenic mutations, new independent risk associations were identified for polymorphic variants in white individuals (M1646T, odds ratio 1·43, 95% CI 1·15-1·78; p=0·0012) and Asian individuals (A419V, 2·27, 1·35-3·83; p=0·0011). A protective haplotype (N551K-R1398H-K1423K) was noted at a frequency greater than 5% in the white and Asian series, with a similar finding in the Arab-Berber series (combined odds ratio 0·82, 0·72-0·94; p=0·0043). Of the two previously reported Asian risk variants, G2385R was associated with disease (1·73, 1·20-2·49; p=0·0026), but no association was noted for R1628P (0·62, 0·36-1·07; p=0·087). In the Arab-Berber series, Y2189C showed potential evidence of risk association with PD (4·48, 1·33-15·09; p=0·012).
INTERPRETATION: The results for LRRK2 show that several rare and common genetic variants in the same gene can have independent effects on disease risk. LRRK2, and the pathway in which it functions, is important in the cause and pathogenesis of PD in a greater proportion of patients with this disease than previously believed. These results will help discriminate those patients who will benefit most from therapies targeted at LRRK2 pathogenic activity. FUNDING: Michael J Fox Foundation and National Institutes of Health.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21885347      PMCID: PMC3208320          DOI: 10.1016/S1474-4422(11)70175-2

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  30 in total

Review 1.  LRRK2 and Parkinson disease.

Authors:  Justus C Dächsel; Matthew J Farrer
Journal:  Arch Neurol       Date:  2010-05

2.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan.

Authors:  Alessio Di Fonzo; Yah-Huei Wu-Chou; Chin-Song Lu; Marina van Doeselaar; Erik J Simons; Christan F Rohé; Hsiu-Chen Chang; Rou-Shayn Chen; Yi-Hsin Weng; Nicola Vanacore; Guido J Breedveld; Ben A Oostra; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2006-04-22       Impact factor: 2.660

3.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

4.  Multiple testing. Part I. Single-step procedures for control of general type I error rates.

Authors:  Sandrine Dudoit; Mark J van der Laan; Katherine S Pollard
Journal:  Stat Appl Genet Mol Biol       Date:  2004-06-09

5.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

6.  Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.

Authors:  Jan O Aasly; Carles Vilariño-Güell; Justus C Dachsel; Philip J Webber; Andrew B West; Kristoffer Haugarvoll; Krisztina K Johansen; Mathias Toft; John G Nutt; Haydeh Payami; Jennifer M Kachergus; Sarah J Lincoln; Amela Felic; Christian Wider; Alexandra I Soto-Ortolaza; Stephanie A Cobb; Linda R White; Owen A Ross; Matthew J Farrer
Journal:  Mov Disord       Date:  2010-10-15       Impact factor: 10.338

7.  Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase.

Authors:  Junpeng Deng; Patrick A Lewis; Elisa Greggio; Eli Sluch; Alexandra Beilina; Mark R Cookson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205

8.  Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease.

Authors:  Alessio Di Fonzo; Cristina Tassorelli; Michele De Mari; Hsin F Chien; Joaquim Ferreira; Christan F Rohé; Giulio Riboldazzi; Angelo Antonini; Gianni Albani; Alessandro Mauro; Roberto Marconi; Giovanni Abbruzzese; Leonardo Lopiano; Emiliana Fincati; Marco Guidi; Paolo Marini; Fabrizio Stocchi; Marco Onofrj; Vincenzo Toni; Michele Tinazzi; Giovanni Fabbrini; Paolo Lamberti; Nicola Vanacore; Giuseppe Meco; Petra Leitner; Ryan J Uitti; Zbigniew K Wszolek; Thomas Gasser; Erik J Simons; Guido J Breedveld; Stefano Goldwurm; Gianni Pezzoli; Cristina Sampaio; Egberto Barbosa; Emilia Martignoni; Ben A Oostra; Vincenzo Bonifati
Journal:  Eur J Hum Genet       Date:  2006-03       Impact factor: 4.246

9.  Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Authors:  Byoung Dae Lee; Joo-Ho Shin; Jackalina VanKampen; Leonard Petrucelli; Andrew B West; Han Seok Ko; Yun-Il Lee; Kathleen A Maguire-Zeiss; William J Bowers; Howard J Federoff; Valina L Dawson; Ted M Dawson
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

10.  Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation.

Authors:  D S Goldstein; R Imrich; E Peckham; C Holmes; G Lopez; C Crews; J Hardy; A Singleton; M Hallett
Journal:  Neurology       Date:  2007-07-11       Impact factor: 9.910

View more
  122 in total

1.  PI3K/Akt/mTOR Signaling and Plasma Membrane Proteins Are Implicated in Responsiveness to Adjuvant Dendritic Cell Vaccination for Metastatic Colorectal Cancer.

Authors:  David C Qian; Xiangjun Xiao; Jinyoung Byun; Arief A Suriawinata; Stephanie C Her; Christopher I Amos; Richard J Barth
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

2.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

3.  Patient-control association study of the Leucine-Rich repeat kinase 2 (LRRK2) gene in South African Parkinson's disease patients.

Authors:  Soraya Bardien; Janine Blanckenberg; Lize van der Merwe; Matthew J Farrer; Owen A Ross
Journal:  Mov Disord       Date:  2013-09-06       Impact factor: 10.338

4.  Missense mutations in TENM4, a regulator of axon guidance and central myelination, cause essential tremor.

Authors:  Hyun Hor; Ludmila Francescatto; Luca Bartesaghi; Sara Ortega-Cubero; Maria Kousi; Oswaldo Lorenzo-Betancor; Felix J Jiménez-Jiménez; Alexandre Gironell; Jordi Clarimón; Oliver Drechsel; José A G Agúndez; Daniela Kenzelmann Broz; Ruth Chiquet-Ehrismann; Alberto Lleó; Francisco Coria; Elena García-Martin; Hortensia Alonso-Navarro; Maria J Martí; Jaume Kulisevsky; Charlotte N Hor; Stephan Ossowski; Roman Chrast; Nicholas Katsanis; Pau Pastor; Xavier Estivill
Journal:  Hum Mol Genet       Date:  2015-07-17       Impact factor: 6.150

5.  Down-regulation of LRRK2 in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicity.

Authors:  Jerome A Roth; Michelle Eichhorn
Journal:  Neurotoxicology       Date:  2013-04-27       Impact factor: 4.294

6.  Association between G2385R and R1628P polymorphism of LRRK2 gene and sporadic Parkinson's disease in a Han-Chinese population in south-eastern China.

Authors:  Jiangping Cai; Yi Lin; Wanjin Chen; Qifang Lin; Bin Cai; Ning Wang; Weihong Zheng
Journal:  Neurol Sci       Date:  2013-04-30       Impact factor: 3.307

7.  Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.

Authors:  Andrew B West; Rita M Cowell; João P L Daher; Mark S Moehle; Kelly M Hinkle; Heather L Melrose; David G Standaert; Laura A Volpicelli-Daley
Journal:  J Comp Neurol       Date:  2014-04-12       Impact factor: 3.215

Review 8.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 9.  The genetics of Parkinson's disease: progress and therapeutic implications.

Authors:  Andrew B Singleton; Matthew J Farrer; Vincenzo Bonifati
Journal:  Mov Disord       Date:  2013-01       Impact factor: 10.338

10.  LRRK2 variation and dementia with Lewy bodies.

Authors:  Michael G Heckman; Alexandra I Soto-Ortolaza; Monica Y Sanchez Contreras; Melissa E Murray; Otto Pedraza; Nancy N Diehl; Ronald Walton; Catherine Labbé; Oswaldo Lorenzo-Betancor; Ryan J Uitti; Jay van Gerpen; Nilüfer Ertekin-Taner; Glenn E Smith; Kejal Kantarci; Rodolfo Savica; David T Jones; Jonathan Graff-Radford; David S Knopman; Val J Lowe; Clifford R Jack; Ronald C Petersen; Joseph E Parisi; Rosa Rademakers; Zbigniew K Wszolek; Neill R Graff-Radford; Tanis J Ferman; Dennis W Dickson; Bradley F Boeve; Owen A Ross
Journal:  Parkinsonism Relat Disord       Date:  2016-07-29       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.